These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 10534354

  • 1. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
    Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T.
    Hepatology; 1999 Nov; 30(5):1302-6. PubMed ID: 10534354
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
    Hoff J, Bani-Sadr F, Gassin M, Raffi F.
    Clin Infect Dis; 2001 Mar 15; 32(6):963-9. PubMed ID: 11247719
    [Abstract] [Full Text] [Related]

  • 3. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, Zaltron S, Puoti M, Carosi G, Torti C.
    Antivir Ther; 2008 Mar 15; 13(3):341-8. PubMed ID: 18572746
    [Abstract] [Full Text] [Related]

  • 4. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG, Lukhwareni A, Song E, Leeuw YG, Burnett RJ, Mphahlele MJ.
    J Med Virol; 2007 Nov 15; 79(11):1650-4. PubMed ID: 17854040
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients].
    Rey D, Fritsch S, Schmitt C, Partisani M, Kempf-Durepaire G, Nicolle M, Krantz V, De Mautort E, Stoll-Keller F, Lang JM.
    Gastroenterol Clin Biol; 2000 Jan 15; 24(1):125-7. PubMed ID: 10679599
    [Abstract] [Full Text] [Related]

  • 9. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC, Haverkamp MH, Weersink AJ, Boucher CA, Hoepelman IM.
    Ned Tijdschr Geneeskd; 2004 Nov 20; 148(47):2330-4. PubMed ID: 15587052
    [Abstract] [Full Text] [Related]

  • 10. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.
    J Med Virol; 2002 Nov 20; 68(3):311-8. PubMed ID: 12226816
    [Abstract] [Full Text] [Related]

  • 11. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA, Sucupira MV, Arabe J, Gomes SA.
    BMC Infect Dis; 2004 Aug 31; 4():29. PubMed ID: 15339340
    [Abstract] [Full Text] [Related]

  • 12. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H.
    Hepatology; 1998 Jun 31; 27(6):1711-6. PubMed ID: 9620347
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
    Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM.
    J Viral Hepat; 2007 Mar 31; 14(3):176-82. PubMed ID: 17305883
    [Abstract] [Full Text] [Related]

  • 15. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
    Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, Mpoudi-Ngolé E, Ducos J, Delaporte E, Laurent C.
    Antivir Ther; 2012 Mar 31; 17(2):321-6. PubMed ID: 22290198
    [Abstract] [Full Text] [Related]

  • 16. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM.
    J Med Virol; 2007 Oct 31; 79(10):1464-71. PubMed ID: 17705185
    [Abstract] [Full Text] [Related]

  • 17. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ.
    J Med Virol; 2002 Oct 31; 68(2):182-7. PubMed ID: 12210406
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
    Aghasadeghi MR, Bahramali G, Sadat SM, Farahani A, Mohraz M, Davar Siadat S, Mostafavi E, Memarnejadian A, Ardestani MS, Vahabpour R, Saraji AA, Delbaz SA.
    Curr HIV Res; 2011 Jun 31; 9(4):263-9. PubMed ID: 21671883
    [Abstract] [Full Text] [Related]

  • 20. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R.
    Liver Transpl; 2001 Feb 31; 7(2):113-7. PubMed ID: 11172394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.